As per reports, the Mankind Pharma latest GMP suggests a premium of Rs 120, suggesting that the scrip will have a remarkable debut on its stock market listing.
Mankind Pharma shares were in very high demand during the three-day share sale via IPO which concluded on April 27 as the issue was subscribed 15.32 times
As per reports, the Mankind Pharma latest GMP suggests a premium of Rs 103, suggesting that the scrip will have a remarkable debut on its stock market listing.